Molecular signatures of intrahepatic cholangiocarcinoma: role in targeted therapy selection

被引：0

作者：

Glushko, Tetiana ^{[1
]}

Costello, James ^{[1
]}

Chima, Ranjit ^{[1
]}

McGettigan, Melissa ^{[1
]}

Kim, Richard ^{[1
]}

Jeong, Daniel ^{[1
]}

Qayyum, Aliya ^{[1
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Radiol, 2902 USF Magnolia Dr, Tampa, FL 33612 USA

来源：

EUROPEAN JOURNAL OF RADIOLOGY | 2025年 / 187卷

关键词：

BILIARY-TRACT CANCER; MUTATIONS; CHEMOTHERAPY; ARID1A; MULTICENTER; EXPRESSION; PROGNOSIS; SURVIVAL; FEATURES; PATHWAY;

D O I：

10.1016/j.ejrad.2025.112056

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Cholangiocarcinoma is a highly lethal disease with a 5-year overall survival rate of 7-20%. A minority of patients present with resectable disease, and relapse rates remain high. Emerging data from next generation sequencing analysis have identified various actionable mutations which drive the different disease courses opening door to precision medicine and targeted therapies. This review focuses on the clinical significance of genetic alterations as well as the role of systemic therapies, immunotherapy and targeted therapies for intrahepatic cholangiocarcinoma.

引用

页数：28

共 50 条

[31] Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma
Cho, Su Min
Esmail, Abdullah
Raza, Ali
Dacha, Sunil
Abdelrahim, Maen
CANCERS, 2022, 14 (11)
[32] Conversion therapy for advanced cholangiocarcinoma in the era of molecular targeted therapy and immune therapy
Zhang, Zunyi
Zhang, Wei
HEPATOBILIARY SURGERY AND NUTRITION, 2023, 12 (05) : 772 - 775
[33] Radioembolization of Intrahepatic Cholangiocarcinoma: Patient Selection, Outcomes, and Competing Therapies
Ness, Joseph Ray
Molvar, Christopher
SEMINARS IN INTERVENTIONAL RADIOLOGY, 2021, 38 (04) : 438 - 444
[34] Neoadjuvant therapy leads to objective response in intrahepatic cholangiocarcinoma
Van Treeck, Benjamin J.
Olave, Maria C.
Watkins, Ryan D.
Lu, Haiyan
Moreira, Roger K.
Mounajjed, Taofic
Johnson, Michael J.
Smith, Carin Y.
Ilyas, Sumera I.
Tran, Nguyen H.
Jenkins, Sarah M.
Reed, Katelyn A.
Smoot, Rory
Mahipal, Amit
Allende, Daniela
Graham, Rondell P.
HPB, 2024, 26 (07) : 938 - 948
[35] Distinct Immune Signatures in Peripheral Blood Predict Chemosensitivity in Intrahepatic Cholangiocarcinoma Patients
Wu, Tong
Yang, Ying-Cheng
Zheng, Bo
Shi, Xue-Bing
Li, Wei
Ma, Wen-Cong
Wang, Shan
Li, Zhi-Xuan
Zhu, Yan-Jing
Wu, Jian-Min
Wang, Kai-Ting
Zhao, Yan
Wu, Rui
Sui, Cheng-Jun
Shen, Si-Yun
Wu, Xuan
Chen, Lei
Yuan, Zhen-Gang
Wang, Hong-Yang
ENGINEERING, 2021, 7 (10) : 1381 - 1392
[36] Advanced and emerging radiation therapy approaches for intrahepatic cholangiocarcinoma
Thonglert, Kanokphorn
Chuong, Michael D.
Herrera, Robert
Apisarnthanarax, Smith
HEPATOMA RESEARCH, 2023, 9
[37] Impact of induction therapy in locally advanced intrahepatic cholangiocarcinoma
Dhote, Alix
Tzedakis, Stylianos
Hobeika, Christian
Marchese, Ugo
Coriat, Romain
Nassar, Alexandra
Beaufrere, Adrelie
Codjia, Tatiana
Goumard, Claire
Scatton, Olivier
Dohan, Anthony
Ronot, Maxime
Terris, Benoit
Lesurtel, Mickael
Dokmak, Safi
Cauchy, Francois
Fuks, David
EJSO, 2023, 49 (10):
[38] Prognostic subclass of intrahepatic cholangiocarcinoma by integrative molecular–clinical analysis and potential targeted approach
Keun Soo Ahn
Daniel O’Brien
Yu Na Kang
Taofic Mounajjed
Yong Hoon Kim
Tae-Seok Kim
Jean-Pierre A. Kocher
Loretta K. Allotey
Mitesh J. Borad
Lewis R. Roberts
Koo Jeong Kang
Hepatology International, 2019, 13 : 490 - 500
[39] FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma
Guion-Dusserre, Jean-Florian
Lorgis, Veronique
Vincent, Julie
Bengrine, Leila
Ghiringhelli, Francois
WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (07) : 2096 - 2101
[40] The role of FGFR inhibitors in the treatment of intrahepatic cholangiocarcinoma-unveiling the future challenges in drug therapy
Nishida, Naoshi
HEPATOBILIARY SURGERY AND NUTRITION, 2023, 12 (05) : 790 - 794

← 1 2 3 4 5 →